mallinckrodt endo merger

Mallinckrodt and Endo plan merger

Mallinckrodt and Endo plan merger as they look to recover from opioid litigation

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in 2025 and at least $150 million of annual operating synergies by year three.

Reuters on MSN · 1d

Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at $6.7 billion. Mallinckrodt Chief Executive Siggi Olafsson said the companies' operations and products complement each other.

The Wall Street Journal on MSN · 1d

Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint.

1don MSN

Mallinckrodt and Endo to combine in stock and cash transaction

Endo (NDOI) stock gains as the company is in pact with Mallinckrodt (MNKTQ) to merge in a $6.7B deal, creating a Dublin-based ...

Mallinckrodt and Endo to combine after emerging from bankruptcy linked to opioid crisis

Mallinckrodt Pharmaceuticals and Endo have agreed to combine in a nearly $7bn deal after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Mallinckrodt and Endo plan merger

Trending now